ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Nov 22, 2022 14:10 JST
Source:
Eisai
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
TOKYO, Nov 22, 2022 - (JCN Newswire) - Shimadzu Corporation (Shimadzu), Eisai Co., Ltd. (Eisai), Oita University, and Usuki City Medical Association hereby announce the commencement of a cohort study using Usuki City as a demonstration site. This joint study will attempt to develop Japan's first diagnostic workflow for mild cognitive impairment (MCI) and Alzheimer's disease (AD) that uses blood biomarkers. In accordance with "Guidelines for Proper Use of Cerebrospinal Fluid and Blood Biomarkers in Dementia"(1), this study aims to demonstrate the utility of blood biomarkers and improve the early diagnosis of Alzheimer's disease within a coordinated system of medical care that encompasses primary care physicians and specialists who are members of dementia-related medical societies.
In cases of Alzheimer's disease, which is said to account for more than 60% of dementia cases, amyloid beta (Abeta, a protein thought to cause AD) starts aggregating in the brain around 20 years before AD onset. Positron emission tomography (amyloid PET) and cerebrospinal fluid (CSF) testing are used to estimate the degree of Aβ accumulation in the brain, but only a limited number of facilities are capable of performing these investigations and the high cost of testing and physical stress involved due to the invasiveness of these investigations also pose a challenge. The increased use of blood biomarkers is expected to reduce the burden on patients.
Study Schema
Usuki City Medical Association will recruit applicants (50 years and older) who wish to participate in the study. Primary care physicians affiliated with Usuki City Medical Association will perform simple cognitive function tests on applicants and select around 200 people with suspected MCI or mild dementia. Specialists affiliated with Usuki City Medical Association Cosmos Hospital (Cosmos Hospital) will then take an in-depth medical history and perform more detailed cognitive function tests before making a final selection of 100 subjects with MCI or mild dementia who are suspected of having Alzheimer's disease. Shimadzu will be responsible for analyzing and evaluating blood biomarker data obtained using Shimadzu's Amyloid MS CL system for measuring amyloid peptides in blood (Amyloid MS CL)(2). Primary care physicians affiliated with Usuki City Medical Association and specialists affiliated with Cosmos Hospital will present and explain test results to participants, evaluate the psychological impact of these results, and provide ongoing medical care as needed. At the Department of Neurology, Faculty of Medicine, Oita University, detailed cognitive function tests will be performed, a self-assessed measurement of brain health will be performed using the "NouKNOW"(3) tool developed by Eisai, Aβ accumulation will be checked by amyloid PET, and the utility of blood biomarkers will be verified. Eisai will use its expertise in dementia research to propose ideas and assist with study planning and provide advice on methods of analyzing and reviewing test results and psychological impact. All four parties will combine findings from evaluating the clinical performance of blood biomarkers and the psychological effects of disclosing test results to ascertain the acceptability of blood biomarkers under actual clinical conditions.
With this joint research, the four parties aim to establish a new diagnostic workflow for Alzheimer's disease that is based on blood biomarkers and includes primary care physicians. Through this work, the four parties are committed to building an ecosystem that improves the early detection of Alzheimer's disease and to developing social infrastructure that allows those concerned and their families to live in peace and security.
(1) Japanese Ministry of Health, Labour and Welfare Grants for Scientific Research, Study Group, March 31, 2021. www.neurology-jp.org/guidelinem/pdf/dementia_biomarker.pdf
(2) Amyloid MS CL is a product that measures amyloid peptides (the main component of amyloid plaques, which are a characteristic feature of Alzheimer's disease) in the blood and provides biomarker data related to amyloid beta levels. In June 2021, Amyloid MS CL was the first product to measure amyloid peptides with a mass spectrometric technique to be approved for use as a medical device in Japan.
(3)""NouKNOW" (non-medical equipment) is a tool developed by Eisai for the self-assessment of brain health (brain performance). "NouKNOW" was developed based on an algorithm created by Cogstate Ltd. for which Eisai holds the exclusive rights for development and commercialization worldwide. "NouKNOW" uses common playing cards displayed on a PC or similar device to test brain response time, attention, visual learning, and memory. "NouKNOW" are registered trademarks of Eisai. Please visit the website for further details
https://nouknow.jp/
For more information, visit www.eisai.com/news/2022/pdf/enews202280pdf.pdf.
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Toyota: Development and Verification of Stationary Storage Battery System Using Electric Vehicle Storage Batteries
May 29, 2023 13:31 JST
Mitsubishi Electric and Mitsubishi Heavy Industries Definitively Agree to Integrate Their Power-generator Systems Businesses
May 29, 2023 11:24 JST
Liquid Hydrogen-Powered Corolla to Participate in the Super Taikyu Fuji 24 Hours Race
May 29, 2023 09:08 JST
Imposing island challenge awaits TOYOTA GAZOO Racing
May 26, 2023 17:35 JST
Results of a Collision Test Conducted on the Driver's Side of a Toyota RAIZE
May 26, 2023 15:07 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26, 2023 14:15 JST
'Fujitsu Technology and Service Vision 2023': sustainability and business converge to solve society's challenges
May 26, 2023 10:12 JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25, 2023 21:02 JST
TOYOTA GAZOO Racing Opens Le Mans 24 Hours Special Website
May 25, 2023 18:28 JST
Hitachi Enhances Diversity, Equity and Inclusion by Supporting LGBTQIA+ Community
May 25, 2023 18:22 JST
Hitachi: Commencement of Joint Studies on Business Initiatives Towards the Development of Sustainable Finance
May 25, 2023 16:10 JST
MHI Thermal Systems to Release Fully Revamped 3HP Model in "HyperInverter" Series of Packaged Air-Conditioners for Domestic Market
May 25, 2023 12:02 JST
SumUp partners with JCB to boost card acceptance for European merchants within its 4-million-strong global network
May 25, 2023 12:00 JST
Mazda 787B to Demonstrate at 24 Hours of Le Mans Centenary Anniversary
May 25, 2023 10:43 JST
Honda to Participate in FIA Formula One World Championship from 2026 Season as Power Unit Supplier for Aston Martin Aramco Cognizant Formula One Team
May 24, 2023 19:01 JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24, 2023 18:03 JST
Mitsubishi Power to Develop Hydrogen-Ready Power Plant for Sembcorp Industries
May 24, 2023 16:06 JST
Mitsubishi Shipbuilding Completes Delivery of Ammonia Fuel Supply System for Large, Low-Speed Two Stroke Marine Engines
May 24, 2023 09:41 JST
More Latest Release >>
Related Release
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
5/26/2023 2:15:00 PM JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
5/25/2023 9:02:00 PM JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
5/24/2023 6:03:00 PM JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
5/20/2023 10:20:00 AM JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
5/16/2023 9:27:00 AM JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
5/8/2023 11:15:00 AM JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
4/6/2023 6:32:00 PM JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
4/4/2023 1:23:00 PM JST
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
4/3/2023 1:06:00 PM JST
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
3/31/2023 4:51:00 PM JST
More Press release >>